MULTI-ANCESTRY WHOLE GENOME SEQUENCING (WGS) AND META-ANALYSIS TO IDENTIFY LOCI ASSOCIATED WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD)

<div><p><b>Background: </b>Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common cause of chronic liver disease in the US. Notably, disease prevalence differs greatly by race/ethnicity, with the highest prevalence in those of Hispanic and Asian ancestry, and the lowest prevalence in those of African ancestry. To date, studies have identified common variants associated with MASLD in predominantly European or American populations.

MORTALITY, HEPATIC DECOMPENSATION, AND CARDIOVASCULAR OUTCOMES IN LEAN VS. NON-LEAN MASH CIRRHOSIS: A VETERANS AFFAIRS COHORT STUDY

<div><p><b>Background: </b>Studies on incident liver and cardiovascular outcomes in lean (body mass index: BMI &lt;25 kg/m<sup>2</sup>, or &lt;23 kg/m<sup>2</sup> for Asians) vs. non-lean individuals with metabolic dysfunction-associated steatohepatitis (MASH) have reported mixed results. We aimed to compare incident clinical outcomes and mortality between lean and non-lean individuals with compensated MASH cirrhosis in a large national cohort.</p>

FIBROSIS IMPROVEMENT WITH PEGOZAFERMIN TREATMENT IN MASH PATIENTS WITH F4 FIBROSIS: ANALYSIS FROM A 24-WEEK RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 TRIAL (ENLIVEN)

<div><p><b>Background:</p> </b><p>Metabolic dysfunction-associated steatohepatitis (MASH) patients who have developed stage F4 fibrosis (cirrhosis) are at risk of hepatic decompensation, hepatocellular carcinoma, liver transplant, cardiovascular events, liver and all-cause mortality. There are currently no approved therapies for non-cirrhotic or cirrhotic MASH.</p>

SERUM Z POLYMER LEVELS AND FACTORS AFFECTING INCREASED LIVER FIBROSIS ARE ASSOCIATED WITH FUTURE SEVERE LIVER DISEASE OUTCOMES IN A PROSPECTIVE COHORT OF ADULTS WITH ALPHA-1-ANTITRYPSIN DEFICIENCY .

<div><p><strong>Background</strong>: <span data-contrast="none" xml:lang="EN-US" lang="EN-US" class="TextRun SCXW199784672 BCX0"><span class="NormalTextRun SCXW199784672 BCX0" data-ccp-charstyle="x_x_normaltextrun">Outcomes of adults with ZZ alpha-1-antitrypsin deficiency (AATD) liver disease is variable and unpredictable. There is a lack of prospective data, including on the utility of liver biopsy.

FEASIBILITY AND RESULTS OF AN INPATIENT TELEHEPATOLOGY CONSULT SERVICE IN AN INTEGRATED HEALTH SYSTEM

<div><p><b>Background: </b>Providers at community hospitals often seek to transfer hospitalized patients with advanced liver disease to tertiary/quaternary care hospitals for further management due to lack of expertise in caring for these patients. However, it is possible to co-manage such patients at local hospitals by providing virtual consultation by tertiary care hepatologists via inpatient telehepatology (INP-TH) consultation.

Subscribe to